Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011 May; 6(5):942-6.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carboplatin
Carcinoma, Non-Small-Cell Lung
Deoxycytidine
Epithelial-Mesenchymal Transition
Female
Gene Amplification
Humans
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Pyrazoles
Pyridines
Receptor Protein-Tyrosine Kinases
Receptors, Growth Factor
Treatment Outcome

authors with profiles

Ravi Salgia